Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future

Decsa Medika Hertanto,1,2 Bayu Satria Wiratama,3,4 Henry Sutanto,5,6 Citrawati Dyah Kencono Wungu7,8 1Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; 2Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia; 3Department of E...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	covid-19 immunomodulation immunology immune system pharmacotherapy coronavirus drug repurposing Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/7358f3b7506d475982ade76f50834948
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7358f3b7506d475982ade76f50834948
record_format	dspace
spelling	oai:doaj.org-article:7358f3b7506d475982ade76f508349482021-12-02T16:17:55ZImmunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future1178-7031https://doaj.org/article/7358f3b7506d475982ade76f508349482021-07-01T00:00:00Zhttps://www.dovepress.com/immunomodulation-as-a-potent-covid-19-pharmacotherapy-past-present-and-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Decsa Medika Hertanto,1,2 Bayu Satria Wiratama,3,4 Henry Sutanto,5,6 Citrawati Dyah Kencono Wungu7,8 1Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; 2Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia; 3Department of Epidemiology, Biostatistics, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 4Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei, Taiwan; 5Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands; 6Department of Physiology and Pharmacology, State University of New York (SUNY) Downstate Health Sciences University, New York, NY, USA; 7Department of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; 8Institute of Tropical Disease, Airlangga University, Surabaya, IndonesiaCorrespondence: Citrawati Dyah Kencono WunguDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, IndonesiaEmail citrawati.dyah@fk.unair.ac.idAbstract: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials have been shown to be ineffective in larger studies. Additionally, the pathophysiology of SARS-CoV-2 infection displayed the predominance of hyperinflammation and immune dysregulation in inducing multiorgan damage. Therefore, the potential benefits of both immune modulation and suppression in COVID-19 have been extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 pharmacological modalities based on the existing data and proposed several new immunologic targets to be tested in the foreseeable future.Keywords: COVID-19, immunomodulation, immunology, immune system, pharmacotherapy, coronavirus, drug repurposingHertanto DMWiratama BSSutanto HWungu CDKDove Medical Pressarticlecovid-19immunomodulationimmunologyimmune systempharmacotherapycoronavirusdrug repurposingPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3419-3428 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 immunomodulation immunology immune system pharmacotherapy coronavirus drug repurposing Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	covid-19 immunomodulation immunology immune system pharmacotherapy coronavirus drug repurposing Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Hertanto DM Wiratama BS Sutanto H Wungu CDK Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
description	Decsa Medika Hertanto,1,2 Bayu Satria Wiratama,3,4 Henry Sutanto,5,6 Citrawati Dyah Kencono Wungu7,8 1Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; 2Department of Internal Medicine, Dr. Soetomo General Hospital, Surabaya, Indonesia; 3Department of Epidemiology, Biostatistics, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; 4Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei, Taiwan; 5Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, the Netherlands; 6Department of Physiology and Pharmacology, State University of New York (SUNY) Downstate Health Sciences University, New York, NY, USA; 7Department of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, Indonesia; 8Institute of Tropical Disease, Airlangga University, Surabaya, IndonesiaCorrespondence: Citrawati Dyah Kencono WunguDepartment of Physiology and Medical Biochemistry, Faculty of Medicine, Airlangga University, Surabaya, IndonesiaEmail citrawati.dyah@fk.unair.ac.idAbstract: In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected more than 150 million individuals and killed 3 million people worldwide. The pandemic has also triggered numerous global initiatives to tackle the newly emerging disease, including the development of SARS-CoV-2 vaccines and the attempt to discover potential pharmacological therapies. Nonetheless, despite the success of SARS-CoV-2 vaccine development, COVID-19 therapy remains challenging. Several repurposed drugs that were documented to be useful in small clinical trials have been shown to be ineffective in larger studies. Additionally, the pathophysiology of SARS-CoV-2 infection displayed the predominance of hyperinflammation and immune dysregulation in inducing multiorgan damage. Therefore, the potential benefits of both immune modulation and suppression in COVID-19 have been extensively discussed. Here, we reviewed the roles of immunomodulation as potential COVID-19 pharmacological modalities based on the existing data and proposed several new immunologic targets to be tested in the foreseeable future.Keywords: COVID-19, immunomodulation, immunology, immune system, pharmacotherapy, coronavirus, drug repurposing
format	article
author	Hertanto DM Wiratama BS Sutanto H Wungu CDK
author_facet	Hertanto DM Wiratama BS Sutanto H Wungu CDK
author_sort	Hertanto DM
title	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
title_short	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
title_full	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
title_fullStr	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
title_full_unstemmed	Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
title_sort	immunomodulation as a potent covid-19 pharmacotherapy: past, present and future
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/7358f3b7506d475982ade76f50834948
work_keys_str_mv	AT hertantodm immunomodulationasapotentcovid19pharmacotherapypastpresentandfuture AT wiratamabs immunomodulationasapotentcovid19pharmacotherapypastpresentandfuture AT sutantoh immunomodulationasapotentcovid19pharmacotherapypastpresentandfuture AT wungucdk immunomodulationasapotentcovid19pharmacotherapypastpresentandfuture
_version_	1718384236957794304

Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future

Ejemplares similares